The National Cancer Institute (NCI) Investigational Drug Steering Committee (IDSC) charged
the Biomarker Task Force to develop recommendations to improve the decisions about …

From a clinical, morphological and molecular perspective, prostate cancer is a heterogeneous
disease. Primary prostate cancers are often multifocal, having topographically and …

A powerful way to discover key genes with causal roles in oncogenesis is to identify
genomic regions that undergo frequent alteration in human cancers. Here we present high-…

High-throughput methods for slide-free three-dimensional (3D) pathological analyses of
whole biopsies and surgical specimens offer the promise of modernizing traditional histology …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …

Therapy for advanced prostate cancer centers on suppressing systemic androgens and
blocking activation of the androgen receptor (AR). Despite anorchid serum androgen levels, …

Androgen deprivation therapy (ADT) remains the primary treatment for advanced prostate
cancer. The efficacy of ADT has not been rigorously evaluated by demonstrating suppression …

Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for
cancers that have metastasized. To determine whether the genomic alterations in a single …

Genes regulated by androgenic hormones are of critical importance for the normal
physiological function of the human prostate gland, and they contribute to the development and …

Androgen receptor (AR) signaling is a distinctive feature of prostate carcinoma (PC) and
represents the major therapeutic target for treating metastatic prostate cancer (mPC). Though …